Global network SalivaDirect has established a broad national and international footprint with over 200 CLIA laboratories using their saliva-based tests and validation in 15+ countries, presenting a scalable opportunity for partnerships, licensing, or expanded testing programs.

Nonprofit agility As a nimble independent nonprofit, SalivaDirect can be a partner for funded health initiatives, public–private collaborations, and grant-aligned pilots that leverage their open-source diagnostic approach to accelerate deployment.

Low-cost diagnostics Their open-source, low-cost COVID-19 assay positions them to offer affordable testing solutions to budget-conscious organizations, universities, and community health programs seeking cost-effective surveillance.

Digital footprint With a lightweight tech stack and established web presence, there are opportunities to offer data integration, analytics, and reporting services to laboratories and health networks seeking streamlined operational insights.

Growth potential Despite a small internal team, the validated international footprint and ongoing focus on saliva-based surveillance suggest potential for collaboration in expanding respiratory pathogen panels, platform licensing, or capacity-building initiatives.